Why the study?
Does upfront spironolactone 25 mg once daily improve safety and natriuresis compared to administration at discharge in acute heart failure patients with cardiorenal syndrome?
Does upfront spironolactone 25 mg once daily improve safety and natriuresis compared to administration at discharge in acute heart failure patients with cardiorenal syndrome?
Upfront administration of spironolactone in acute heart failure with cardiorenal syndrome appears safe regarding potassium levels and significantly increases 24-hour natriuresis compared to administration at discharge.
No takes yet. Share an insight, caveat, or question.
Supports safe upfront spironolactone initiation with greater natriuresis in acute HF; extends evidence for early MRA use in cardiorenal syndrome.
Verbrugge et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: